Gilead Sciences annual total debt
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Gilead Sciences Total Debt Growth & History (GILD)
Gilead Sciences's total debt was $25.54B for fiscal 2025.
View full Gilead Sciences company overviewGilead Sciences annual total debt history
| Fiscal year | Period ended | Total debt | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $25.54B | −$1.78B | −6.52% |
| 2024 | 2024-12-31 | $27.32B | $1.66B | +6.49% |
| 2023 | 2023-12-31 | $25.66B | −$150.0M | −0.58% |
| 2022 | 2022-12-31 | $25.81B | −$1.48B | −5.41% |
| 2021 | 2021-12-31 | $27.29B | −$4.83B | −15.04% |
| 2020 | 2020-12-31 | $32.12B | $6.80B | +26.85% |
| 2019 | 2019-12-31 | $25.32B | −$2.00B | −7.33% |
| 2018 | 2018-12-31 | $27.32B | −$6.22B | −18.54% |
| 2017 | 2017-12-31 | $33.54B | $7.20B | +27.31% |
| 2016 | 2016-12-31 | $26.35B | $4.29B | +19.46% |
| 2015 | 2015-12-31 | $22.05B | $9.65B | +77.86% |
| 2014 | 2014-12-31 | $12.40B | $5.76B | +86.86% |
| 2013 | 2013-12-31 | $6.64B | −$1.59B | −19.31% |
| 2012 | 2012-12-31 | $8.22B | $616.7M | +8.11% |
| 2011 | 2011-12-31 | $7.61B | $3.48B | +84.36% |
| 2010 | 2010-12-31 | $4.13B | $2.97B | +255.40% |
| 2009 | 2009-12-31 | $1.16B | $57.4M | +5.20% |
| 2008 | 2008-12-31 | $1.10B | — | — |
Gilead Sciences quarterly total debt
Q4.08
Q2.09
Q3.09
Q4.09
Q1.10
Q3.10
Q4.10
Q1.11
Q2.11
Q3.11
Q4.11
Q1.12
Q2.12
Q3.12
Q4.12
Q1.13
Q2.13
Q3.13
Q4.13
Q1.14
Q2.14
Q3.14
Q4.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Total debt | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $26.25B | $1.30B | +5.21% |
| Q1 2026 | 2026-03-31 | $22.17B | −$2.78B | −11.13% |
| Q4 2025 | 2025-12-31 | $25.54B | −$1.78B | −6.52% |
| Q3 2025 | 2025-09-30 | $24.94B | $1.69B | +7.28% |
| Q2 2025 | 2025-06-30 | $24.95B | $1.60B | +6.84% |
| Q1 2025 | 2025-03-31 | $24.95B | −$242.0M | −0.96% |
| Q4 2024 | 2024-12-31 | $27.32B | $1.66B | +6.49% |
| Q3 2024 | 2024-09-30 | $23.25B | −$1.73B | −6.94% |
| Q2 2024 | 2024-06-30 | $23.35B | −$1.90B | −7.51% |
| Q1 2024 | 2024-03-31 | $25.19B | −$45.0M | −0.18% |
| Q4 2023 | 2023-12-31 | $25.66B | −$150.0M | −0.58% |
| Q3 2023 | 2023-09-30 | $24.98B | −$241.0M | −0.96% |
| Q2 2023 | 2023-06-30 | $25.25B | −$970.0M | −3.70% |
| Q1 2023 | 2023-03-31 | $25.24B | −$969.0M | −3.70% |
| Q4 2022 | 2022-12-31 | $25.81B | −$1.48B | −5.41% |
| Q3 2022 | 2022-09-30 | $25.22B | −$2.46B | −8.90% |
| Q2 2022 | 2022-06-30 | $26.22B | −$3.96B | −13.12% |
| Q1 2022 | 2022-03-31 | $26.21B | −$3.96B | −13.12% |
| Q4 2021 | 2021-12-31 | $27.29B | −$4.83B | −15.04% |
| Q3 2021 | 2021-09-30 | $27.69B | −$1.60B | −5.48% |
| Q2 2021 | 2021-06-30 | $30.18B | $6.07B | +25.20% |
| Q1 2021 | 2021-03-31 | $30.17B | $6.07B | +25.19% |
| Q4 2020 | 2020-12-31 | $32.12B | $6.80B | +26.85% |
| Q3 2020 | 2020-09-30 | $29.29B | $3.99B | +15.77% |
| Q2 2020 | 2020-06-30 | $24.10B | −$2.54B | −9.52% |
| Q1 2020 | 2020-03-31 | $24.10B | −$2.98B | −11.02% |
| Q4 2019 | 2019-12-31 | $25.32B | −$2.00B | −7.33% |
| Q3 2019 | 2019-09-30 | $25.30B | −$2.02B | −7.38% |
| Q2 2019 | 2019-06-30 | $26.64B | −$2.42B | −8.34% |
| Q1 2019 | 2019-03-31 | $27.08B | −$1.97B | −6.79% |
| Q4 2018 | 2018-12-31 | $27.32B | −$6.22B | −18.54% |
| Q3 2018 | 2018-09-30 | $27.32B | −$1.95B | −6.65% |
| Q2 2018 | 2018-06-30 | $29.06B | $2.76B | +10.51% |
| Q1 2018 | 2018-03-31 | $29.05B | $2.73B | +10.38% |
| Q4 2017 | 2017-12-31 | $33.54B | $7.20B | +27.31% |
| Q3 2017 | 2017-09-30 | $29.26B | $2.19B | +8.09% |
| Q2 2017 | 2017-06-30 | $26.30B | $4.17B | +18.84% |
| Q1 2017 | 2017-03-31 | $26.32B | $4.29B | +19.48% |
| Q4 2016 | 2016-12-31 | $26.35B | $4.29B | +19.46% |
| Q3 2016 | 2016-09-30 | $27.07B | $4.85B | +21.80% |
| Q2 2016 | 2016-06-30 | $22.13B | $9.85B | +80.28% |
| Q1 2016 | 2016-03-31 | $22.03B | $9.67B | +78.19% |
| Q4 2015 | 2015-12-31 | $22.05B | $9.65B | +77.86% |
| Q3 2015 | 2015-09-30 | $22.23B | $12.81B | +136.18% |
| Q2 2015 | 2015-06-30 | $12.27B | $2.77B | +29.14% |
| Q1 2015 | 2015-03-31 | $12.36B | $2.56B | +26.10% |
| Q4 2014 | 2014-12-31 | $12.40B | $5.76B | +86.86% |
| Q3 2014 | 2014-09-30 | $9.41B | $2.10B | +28.67% |
| Q2 2014 | 2014-06-30 | $9.50B | $2.17B | +29.53% |
| Q1 2014 | 2014-03-31 | $9.80B | $1.81B | +22.58% |
| Q4 2013 | 2013-12-31 | $6.64B | −$1.59B | −19.31% |
| Q3 2013 | 2013-09-30 | $7.31B | −$1.46B | −16.62% |
| Q2 2013 | 2013-06-30 | $7.34B | −$1.76B | −19.36% |
| Q1 2013 | 2013-03-31 | $8.00B | −$1.43B | −15.18% |
| Q4 2012 | 2012-12-31 | $8.22B | $616.7M | +8.11% |
| Q3 2012 | 2012-09-30 | $8.77B | $8.77B | +552595.46% |
| Q2 2012 | 2012-06-30 | $9.10B | $9.09B | +123782.82% |
| Q1 2012 | 2012-03-31 | $9.43B | $8.78B | +1343.72% |
| Q4 2011 | 2011-12-31 | $7.61B | $3.48B | +84.36% |
| Q3 2011 | 2011-09-30 | $1.6M | −$3.45B | −99.95% |
| Q2 2011 | 2011-06-30 | $7.3M | — | — |
| Q1 2011 | 2011-03-31 | $653.1M | −$524.1M | −44.52% |
| Q4 2010 | 2010-12-31 | $4.13B | $2.97B | +255.40% |
| Q3 2010 | 2010-09-30 | $3.45B | $2.10B | +156.30% |
| Q1 2010 | 2010-03-31 | $1.18B | — | — |
| Q4 2009 | 2009-12-31 | $1.16B | $57.4M | +5.20% |
| Q3 2009 | 2009-09-30 | $1.35B | — | — |
| Q2 2009 | 2009-06-30 | $1.53B | — | — |
| Q4 2008 | 2008-12-31 | $1.10B | — | — |
Gilead Sciences total debt trends
Over the last five fiscal years, Gilead Sciences's total debt decreased from $32.12B to $25.54B, a change of −$6.58B. The latest reported quarter, Q2 2026, shows $26.25B.
About the metric
What total debt means
Total debt measures a company’s reported interest-bearing borrowing obligations at a reporting-period end. It can include short-term borrowings, current maturities, long-term debt, and finance lease obligations when they are included in the company’s debt facts.
Calculation and source
SEC-reported and combined total debt
TickerStat uses a reported aggregate debt value when available. Otherwise, it combines non-overlapping current and noncurrent debt facts from SEC filings. Total liabilities are not treated as debt, and missing debt is not assumed to be zero. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Gilead Sciences source filings ↗Community posts
Gilead raises its sales outlook but projects a deeper acquisition-driven annual loss
Gilead ($GILD) increased its 2026 product-sales forecast to $31.0–$31.3 billion from $30.1–$30.4 billion after third-quarter 2026 product revenue rose 13% to $8.3 billion. HIV sales grew 18% to $6.2 billion, supported by demand, pricing and ...
Gilead agrees $1.275 billion purchase of PepStar's oral inflammation program
Gilead ($GILD) agreed to acquire worldwide rights to PepStar's investigational oral IL-23 receptor inhibitor program, led by HCXT-2001. The agreement calls for $1.275 billion in upfront cash consideration payable at closing, subject to cust ...
